Maharashtra FDA steps up scrutiny of Vimal Elaichi celebrity ads

Maharashtra FDA chief Tukaram Mundhe said celebrity influence does not override public-health law, backing the President’s call against harmful-product endorsements. The agency has issued notices to three actors over Vimal Elaichi ads it says may surrogate-promote prohibited Vimal Pan Masala, raising compliance and reputation risk for the brand.

— Source publishedWed, 23 Sept, 2026, 17:41 IST·First seen Wed, 23 Sept, 2026, 18:05 IST·Source Business Today · Latest

What happened

Vimal · Maharashtra FDA chief Tukaram Mundhe backed President Murmu’s call against harmful-product endorsements, stressing celebrity influence does not override

Key facts

  • 72nd National Film Awards
  • August 11
  • three actors

Why this matters

Treat tobacco-, pan masala- and surrogate-advertising exposure as a heightened diligence issue, with regulatory contingencies and endorsement-risk clauses in any transaction.

What to watch

  • Whether Maharashtra FDA orders ad withdrawal, imposes penalties, or refers the matter to central consumer or food-safety authorities.
  • Notices or investigations by other state FDAs, CCPA, Ministry of Information and Broadcasting, or ASCI involving Vimal or comparable pan masala-linked brands.
  • Celebrity statements, contract exits, or refusal by broadcasters, OTT platforms, and digital platforms to carry the ads.
  • Evidence of shared visual identity, trademarks, pack design, slogans, or distribution between Vimal Elaichi and Vimal Pan Masala.
  • Any court challenge or formal clarification defining the threshold for surrogate advertising of otherwise legal FMCG products.
  • Pause or geo-fence Maharashtra-facing celebrity creative until notice responses and claim substantiation are reviewed.
  • Separate Vimal Elaichi branding, packaging, distribution, and messaging more visibly from pan masala identifiers to reduce surrogate-promotion inference.
  • Prepare actor-specific compliance briefs and indemnity protocols; expect talent contracts to add morality, regulatory-exit, and campaign-withdrawal clauses.
  • Shift near-term media spending toward product-information, retailer activation, and non-celebrity assets that can survive stricter ad review.
  • Engage ASCI, broadcasters, platforms, and legal counsel proactively to align disclosures and avoid synchronized takedowns across channels.